Статті в журналах з теми "FDA-approved drug"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 статей у журналах для дослідження на тему "FDA-approved drug".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
Gould, Stephen J. "AIDS and FDA Drug-Approved Policy:." Journal of Health & Social Policy 2, no. 2 (February 21, 1991): 39–46. http://dx.doi.org/10.1300/j045v02n02_03.
Повний текст джерелаVokinger, Kerstin Noëlle, and Aaron S. Kesselheim. "Application of orphan drug designation to cancer treatments (2008–2017): a comprehensive and comparative analysis of the USA and EU." BMJ Open 9, no. 10 (October 2019): e028634. http://dx.doi.org/10.1136/bmjopen-2018-028634.
Повний текст джерелаZhong, Hao, Ging Chan, Yuanjia Hu, Hao Hu, and Defang Ouyang. "A Comprehensive Map of FDA-Approved Pharmaceutical Products." Pharmaceutics 10, no. 4 (December 6, 2018): 263. http://dx.doi.org/10.3390/pharmaceutics10040263.
Повний текст джерелаEzeife, Doreen Anuli, Patricia Tang, Daniel Yick Chin Heng, and Stephen Welch. "Comparison of drug approval between health Canada (HC) and the U.S. Food and Drug Administration (FDA)." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 6082. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.6082.
Повний текст джерелаSaberian, Nafiseh, Azam Peyvandipour, Michele Donato, Sahar Ansari, and Sorin Draghici. "A new computational drug repurposing method using established disease–drug pair knowledge." Bioinformatics 35, no. 19 (March 6, 2019): 3672–78. http://dx.doi.org/10.1093/bioinformatics/btz156.
Повний текст джерелаHershman, Dawn L., Alfred I. Neugut, Donna Buono, Catherine A. Richards, Sherry A. Glied, and Jason Dennis Wright. "Off-label and compendia use of chemotherapy in patients with metastatic cancer." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 6509. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.6509.
Повний текст джерелаNair, Aathira Sujathan, Ashutosh Kumar Singh, Astik Kumar, Sunil Kumar, Sunitha Sukumaran, Vishal Payyalot Koyiparambath, Leena K. Pappachen, T. M. Rangarajan, Hoon Kim, and Bijo Mathew. "FDA-Approved Trifluoromethyl Group-Containing Drugs: A Review of 20 Years." Processes 10, no. 10 (October 11, 2022): 2054. http://dx.doi.org/10.3390/pr10102054.
Повний текст джерелаKlasmeier, Coleen, and Martin H. Redish. "Off-Label Prescription Advertising, the FDA and the First Amendment: A Study in the Values of Commercial Speech Protection." American Journal of Law & Medicine 37, no. 2-3 (June 2011): 315–57. http://dx.doi.org/10.1177/009885881103700206.
Повний текст джерелаLosben, Nancy L. "2020: A Record Year for Drug Approvals." Senior Care Pharmacist 36, no. 4 (April 1, 2021): 174–75. http://dx.doi.org/10.4140/tcp.n.2021.174.
Повний текст джерелаRizzo, Carla, Sara Amata, Ivana Pibiri, Andrea Pace, Silvestre Buscemi, and Antonio Palumbo Piccionello. "FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022." International Journal of Molecular Sciences 24, no. 9 (April 23, 2023): 7728. http://dx.doi.org/10.3390/ijms24097728.
Повний текст джерелаKim, Jeeyun A., Rachel Ceccarelli, and Christine Y. Lu. "Pharmacogenomic Biomarkers in US FDA-Approved Drug Labels (2000–2020)." Journal of Personalized Medicine 11, no. 3 (March 4, 2021): 179. http://dx.doi.org/10.3390/jpm11030179.
Повний текст джерелаCeccoli, Stephen J. "Policy Punctuations and Regulatory Drug Review." Journal of Policy History 15, no. 2 (April 2003): 157–91. http://dx.doi.org/10.1353/jph.2003.0011.
Повний текст джерелаGnanasakthy, Ari, Carla DeMuro, Marci Clark, Emily Haydysch, Esprit Ma, and Vijayveer Bonthapally. "Patient-Reported Outcomes Labeling for Products Approved by the Office of Hematology and Oncology Products of the US Food and Drug Administration (2010-2014)." Journal of Clinical Oncology 34, no. 16 (June 1, 2016): 1928–34. http://dx.doi.org/10.1200/jco.2015.63.6480.
Повний текст джерелаChopra, S., M. Torres-Ortiz, L. Hokama, P. Madrid, M. Tanga, K. Mortelmans, K. Kodukula, and A. K. Galande. "Repurposing FDA-approved drugs to combat drug-resistant Acinetobacter baumannii." Journal of Antimicrobial Chemotherapy 65, no. 12 (September 22, 2010): 2598–601. http://dx.doi.org/10.1093/jac/dkq353.
Повний текст джерелаDesai, Bansri, Kyungwan Hong, John H. Powers, and Peter Doshi. "Reporting of Drug Benefit in FDA-Approved Prescription Drug Labeling." Journal of General Internal Medicine 35, no. 1 (October 28, 2019): 377–79. http://dx.doi.org/10.1007/s11606-019-05460-2.
Повний текст джерела&NA;. "New anti-Parkinsonian drug approved by US FDA." Inpharma Weekly &NA;, no. 1095 (July 1997): 22. http://dx.doi.org/10.2165/00128413-199710950-00044.
Повний текст джерелаDeWitt, Sheila H., and Bruce E. Maryanoff. "Deuterated Drug Molecules: Focus on FDA-Approved Deutetrabenazine." Biochemistry 57, no. 5 (November 21, 2017): 472–73. http://dx.doi.org/10.1021/acs.biochem.7b00765.
Повний текст джерелаWetzel, Carlie, Mitchell Lonneman, and Chun Wu. "Polypharmacological drug actions of recently FDA approved antibiotics." European Journal of Medicinal Chemistry 209 (January 2021): 112931. http://dx.doi.org/10.1016/j.ejmech.2020.112931.
Повний текст джерелаDo, Michael, Bona Shin, Elaina Lioudis, and Emaleigh Munn. "Novel Drugs Approved in 2021-2022." Transformative Medicine 1, no. 3 (September 2022): 72–77. http://dx.doi.org/10.54299/tmed/zcno1399.
Повний текст джерелаRodwin, Marc A. "Rooting Out Institutional Corruption to Manage Inappropriate Off-Label Drug Use." Journal of Law, Medicine & Ethics 41, no. 3 (2013): 654–64. http://dx.doi.org/10.1111/jlme.12075.
Повний текст джерелаOmae, Kenji, Yuki Kataoka, Yasushi Tsujimoto, Yusuke Tsutsumi, Shunichi Fukuhara, and Toshi Furukawa. "Publication statuses of clinical trials supporting immune checkpoint inhibitors recently approved by the United States Food and Drug Administration: A meta-epidemiological investigation." Journal of Clinical Oncology 37, no. 8_suppl (March 10, 2019): 89. http://dx.doi.org/10.1200/jco.2019.37.8_suppl.89.
Повний текст джерелаHamrell, Michael R., Marilyn N. Martinez, Shrikant V. Dighe, and Paul D. Parkman. "Bioequivalence of Generic Thioridazine Drug Products—The FDA Viewpoint." Drug Intelligence & Clinical Pharmacy 21, no. 4 (April 1987): 362–69. http://dx.doi.org/10.1177/106002808702100413.
Повний текст джерелаGoodman, Aaron M., Michael Choi, Matthew Wieduwilt, Carolyn Mulroney, Caitlin Costello, Garrett Frampton, Vincent Miller, and Razelle Kurzrock. "Next-Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients With Lymphoid Malignancies." JCO Precision Oncology, no. 1 (November 2017): 1–13. http://dx.doi.org/10.1200/po.16.00004.
Повний текст джерелаReddy, D. Samba, and Savitha Reddy. "The Novel Drugs of 2015 – An Extraordinary Growth of Innovative Pharmaceuticals." International Journal of Pharmaceutical Sciences and Nanotechnology 9, no. 4 (July 31, 2016): 3331–36. http://dx.doi.org/10.37285/ijpsn.2016.9.4.1.
Повний текст джерелаMiller, Jennifer E., Marc Wilenzick, Nolan Ritcey, Joseph S. Ross, and Michelle M. Mello. "Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies." BMJ Open 7, no. 12 (December 2017): e017917. http://dx.doi.org/10.1136/bmjopen-2017-017917.
Повний текст джерелаLindstrom, Jill A. "Sources of drug information: FDA-approved labeling and other official FDA sources." Dermatologic Therapy 22, no. 3 (May 2009): 246–56. http://dx.doi.org/10.1111/j.1529-8019.2009.01238.x.
Повний текст джерелаMonge, Andrea N., Daniel W. Sigelman, Robert J. Temple, and Harinder Singh Chahal. "Use of US Food and Drug Administration Expedited Drug Development and Review Programs by Orphan and Nonorphan Novel Drugs Approved From 2008 to 2021." JAMA Network Open 5, no. 11 (November 1, 2022): e2239336. http://dx.doi.org/10.1001/jamanetworkopen.2022.39336.
Повний текст джерелаGonzalez, Misty L. "New Drug Review-Ezogabine (Potiga): Seizing the seizure." Mental Health Clinician 1, no. 6 (December 1, 2011): 135–36. http://dx.doi.org/10.9740/mhc.n89803.
Повний текст джерелаSochacka-Ćwikła, Aleksandra, Marcin Mączyński, and Andrzej Regiec. "FDA-Approved Drugs for Hematological Malignancies—The Last Decade Review." Cancers 14, no. 1 (December 24, 2021): 87. http://dx.doi.org/10.3390/cancers14010087.
Повний текст джерелаTaylor, Richard D., Malcolm MacCoss, and Alastair D. G. Lawson. "Combining Molecular Scaffolds from FDA Approved Drugs: Application to Drug Discovery." Journal of Medicinal Chemistry 60, no. 5 (December 23, 2016): 1638–47. http://dx.doi.org/10.1021/acs.jmedchem.6b01367.
Повний текст джерелаGable, Kelly N. "New Drug Review: Lurasidone (Latuda®) - The new antipsychotic on the block." Mental Health Clinician 1, no. 6 (December 1, 2011): 131–32. http://dx.doi.org/10.9740/mhc.n89387.
Повний текст джерелаGable, Kelly N. "Saphris: Does a unique delivery system equal a unique drug?" Mental Health Clinician 1, no. 6 (December 1, 2011): 133–34. http://dx.doi.org/10.9740/mhc.n89388.
Повний текст джерелаAl Shaer, Danah, Othman Al Musaimi, Fernando Albericio, and Beatriz de la Torre. "2018 FDA Tides Harvest." Pharmaceuticals 12, no. 2 (April 5, 2019): 52. http://dx.doi.org/10.3390/ph12020052.
Повний текст джерелаKumar Shukla, Ajay, Kumar Shukla, Rekha Mehani, Swati Jain, and Sheema Maqsood. "Analysis of FDA Novel Drug Approvals." Biomedical and Pharmacology Journal 14, no. 1 (March 28, 2021): 225–33. http://dx.doi.org/10.13005/bpj/2117.
Повний текст джерелаHuey, Ryan, Seerat Anand, Jane Elizabeth Rogers, Arvind Dasari, Gauri Rajani Varadhachary, Anirudh Gothwal, Jonathan M. Loree, Lee M. Ellis, Michael J. Overman, and Kanwal Pratap Singh Raghav. "Value appraisal of FDA approved cancer drugs over the past decade." Journal of Clinical Oncology 37, no. 27_suppl (September 20, 2019): 115. http://dx.doi.org/10.1200/jco.2019.37.27_suppl.115.
Повний текст джерелаHuey, Ryan, Seerat Anand, Jane Rogers, Arvind Dasari, Gauri Rajani Varadhachary, Anirudh Gothwal, Jonathan M. Loree, Lee M. Ellis, Michael J. Overman, and Kanwal Pratap Singh Raghav. "Value appraisal of FDA approved cancer drugs over the past decade." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): e18385-e18385. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e18385.
Повний текст джерелаHolmes, Jamie, and Robin Hieber. "New Drug Review: Clobazam (Onfi®) - A “new” anticonvulsant option." Mental Health Clinician 1, no. 6 (December 1, 2011): 126–27. http://dx.doi.org/10.9740/mhc.n89385.
Повний текст джерелаNewton, Uma, and Tiffany-Jade Kreys. "Iloperidone (Fanapt®): Fan or not?" Mental Health Clinician 1, no. 6 (December 1, 2011): 137–39. http://dx.doi.org/10.9740/mhc.n89390.
Повний текст джерелаWerremeyer, Amy B. "New Drug Review: Gabapentin enacarbil extended release (Horizant™) – A new formulation on the horizon." Mental Health Clinician 1, no. 6 (December 1, 2011): 128–30. http://dx.doi.org/10.9740/mhc.n89391.
Повний текст джерелаGonzalez, Misty L. "Viibryd (Vilazodone): Viable option or for the byrds?" Mental Health Clinician 1, no. 6 (December 1, 2011): 140–41. http://dx.doi.org/10.9740/mhc.n89810.
Повний текст джерелаChancey, Rebecca J., Yon Yu, Patricia Yu, Julian Jolly, and Susan Montgomery. "770. Otherwise Unavailable Non-Malarial Parasitic Disease Treatment Drugs in the United States: an Update from CDC Parasitic Diseases Drug Service." Open Forum Infectious Diseases 7, Supplement_1 (October 1, 2020): S429—S430. http://dx.doi.org/10.1093/ofid/ofaa439.960.
Повний текст джерелаAKERMI, SARRA, Neha Lohar, Subrata Sinha, Surabhi Johari, Sunil Jayant, and Anshul Nigam. "In-silico identification of natural antiviral drug against SARS-CoV-2 and comparison with potential FDA approved drug targets." Journal of Science 3, no. 4 (September 5, 2020): 1–11. http://dx.doi.org/10.47944/jos.3.4.2020.1.
Повний текст джерелаVokinger, Kerstin Noëlle, Paola Daniore, Thomas J. Hwang, ChangWon C. Lee, and Aaron S. Kesselheim. "Pivotal trial endpoints and prices of cancer drugs in the US and Europe." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): 2077. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.2077.
Повний текст джерелаShabir, Ghulam, Aamer Saeed, Wajeeha Zahid, Fatima Naseer, Zainab Riaz, Nafeesa Khalil, Muneeba, and Fernando Albericio. "Chemistry and Pharmacology of Fluorinated Drugs Approved by the FDA (2016–2022)." Pharmaceuticals 16, no. 8 (August 15, 2023): 1162. http://dx.doi.org/10.3390/ph16081162.
Повний текст джерелаBeinse, Guillaume, Virgile Tellier, Valentin Charvet, Eric Deutsch, Isabelle Borget, Christophe Massard, Antoine Hollebecque, and Loic Verlingue. "Prediction of Drug Approval After Phase I Clinical Trials in Oncology: RESOLVED2." JCO Clinical Cancer Informatics, no. 3 (December 2019): 1–10. http://dx.doi.org/10.1200/cci.19.00023.
Повний текст джерелаKhaki, Ali Raza, Aakash Desai, Martin W. Schoen, Bishal Gyawali, Eddy J. Chen, Peter C. Yang, and Jeremy Lyle Warner. "Timing of US Food and Drug Administration (FDA) cancer drug approvals relative to publication of clinical trial results." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): 2071. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.2071.
Повний текст джерелаChen, Charles H., and Timothy K. Lu. "Development and Challenges of Antimicrobial Peptides for Therapeutic Applications." Antibiotics 9, no. 1 (January 13, 2020): 24. http://dx.doi.org/10.3390/antibiotics9010024.
Повний текст джерелаReddy, Neha K., Jason Roszik, David Carl Norris, Roman Groisberg, Niamh Coleman, Omar Alhalabi, Ethan B. Ludmir, Cullen M. Taniguchi, Ishwaria Mohan Subbiah, and Vivek Subbiah. "Dosing, drug reduction, drug interruption, and drug discontinuation rates among U.S. FDA approved tyrosine kinase inhibitors." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): 3112. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.3112.
Повний текст джерелаRodriguez-Monguio, Rosa, Enrique Seoane-Vazquez, and John H. Powers. "A Comparative Assessment of Approvals and Discontinuations of Systemic Antibiotics and Other Therapeutic Areas." Healthcare 11, no. 12 (June 15, 2023): 1759. http://dx.doi.org/10.3390/healthcare11121759.
Повний текст джерелаVadola, Lisa Ambrosini, Monique A. Pond, Ann Winter-Vann, and Robin Whitsell. "Faster approvals?: Trends in the use of FDA’s expedited approval programs for oncology medications." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): e18270-e18270. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e18270.
Повний текст джерела